Items Tagged ‘cyclin-dependent kinase’

December 12th, 2017

Kisqali® Improves Outcomes of Premenopausal Women with HR+/HER2- Advanced Breast Cancer

By

It was announced today that results from the Phase III MONALEESA-7 trial evaluating Kisqali® (ribociclib) in combination endocrine-based therapy in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2017 Annual San Antonio Breast Cancer […]

View full entry

Tags: advanced breast cancer, Breast Cancer, cyclin-dependent kinase, inhibitor, kisqali, MONELESSA 7, News, Precision Cancer Medicine, premenopausal, ribociclib, San Antonio Breast Cancer Symposium


October 30th, 2017

Verzenio Demonstrates Superior Progression-Free Survival in Advanced Breast Cancer

By

Recently released clinical trial results from the Phase 3 MONARCH 2 study showed that Verzenio (abemaciclib), a cyclin-dependent kinase (CDK) 4 & 6 inhibitor, when administered in combination with fulvestrant, significantly improves the time to cancer progression compared to treatment with fulvestrant alone in women with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), […]

View full entry

Tags: 4 & 6 inhibitor, abemaciclib, advanced breast cancer, Breast Cancer, CDK, cyclin-dependent kinase, News, Phase 3 MONARCH 2, Precision Cancer Medicine, Verzenio